3629 results for «25»
3629 results
Asymptomatic high-risk patients: can CT coronary angiography improve our practice?
21 May 2026 – From EuroPCR 2026
This session examines the role of cardiac computed tomography (CT) coronary angiography in improving clinical practice for asymptomatic high-risk patients. It discusses detection of vulnerable plaque features, the importance of inflammation and physiology in risk assessment, and explores individualized treatment pathways including PCI, medical therapy, or...
Ambiguous left main lesions: how to assess severity and make the right decision
21 May 2026 – From EuroPCR 2026
Addressing the complexities of ambiguous left main coronary lesions, this session elucidates the integration of physiology, intracoronary imaging, and CT scanning for comprehensive assessment. It highlights multimodality diagnostic strategies and decision-making frameworks to guide appropriate revascularization.
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
Hybrid percutaneous revascularisation: combining DES and DCB for optimal results
21 May 2026 – From EuroPCR 2026
This session delves into hybrid percutaneous revascularisation techniques that combine drug-eluting stents (DES) and drug-coated balloons (DCB) to achieve optimal clinical results. It highlights the clinical and anatomical scenarios suited for hybrid PCI, provides a step-by-step procedural approach, and discusses the potential benefits of integrating these...
All you need to know of DAPT in ACS
21 May 2026 – From EuroPCR 2026
This session provides an in-depth review of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS), focusing on strategies for safe de-escalation and P2Y12 inhibitor monotherapy to reduce bleeding risk without compromising ischemic protection. It also covers optimizing antithrombotic therapy in patients on oral anticoagulation and...
DCB: what we know and what we do not know
22 May 2026 – From EuroPCR 2026
This session provides a detailed update on drug-coated balloons (DCB) in interventional cardiology, covering the latest clinical data and trials. It identifies scenarios where DCB use is most effective and offers guidance on optimizing procedural techniques to enhance clinical outcomes.
Insight from recent evidence in structural heart disease: indications for LAA closure (CHAMPION) and PCI in TAVI candidates (PRO-TAVI)
20 May 2026 – From EuroPCR 2026
This session reviews recent evidence impacting the management of structural heart disease, focusing on left atrial appendage (LAA) closure indications and PCI considerations in transcatheter aortic valve implantation (TAVI) candidates. It discusses optimal strategies for coronary artery disease in TAVI patients and evaluates findings from the...
Back to the future - Lessons from the past that can guide contemporary practice
20 May 2026 – From EuroPCR 2026
Reflecting on historical perspectives in the management of atherosclerotic coronary vascular disease, this session imparts valuable lessons to guide contemporary PCI practice. It emphasizes best practices in vessel preparation, evaluates the significance of drug-eluting stents, and provides a pathologist’s insight into mechanisms of PCI failure to...
Insight from recent evidence in coronary artery disease: value of DCB for de novo lesions (SELUTION) and imaging for left main PCI (OPTIMAL)
21 May 2026 – From EuroPCR 2026
This session reviews pivotal recent evidence impacting daily practice in coronary artery disease management. It discusses the role of drug-coated balloons (DCB) for de novo lesions as evaluated in the SELUTION trial and evaluates intracoronary imaging strategies for left main PCI as presented in the OPTIMAL...
